Alkermes (ALKS) Cash from Operations (2010 - 2026)
Alkermes' (ALKS) quarterly Cash from Operations came in at 165743000.0 in Q1 2026, down 267.74% year-on-year from 98811000.0 in Q1 2025, and down 197.46% on a QoQ basis from 170069000.0 in Q4 2025.
Alkermes (ALKS) Cash from Operations (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has 17 years of Cash from Operations data on file, last reported at 165743000.0 in Q1 2026.
- On a quarterly basis, Cash from Operations fell 267.74% year-over-year to 165743000.0 in Q1 2026; TTM through Mar 2026 was 256200000.0, a 50.43% decrease from a year earlier, with the FY2025 full-year figure at 520754000.0, up 18.59% from the prior year.
- Cash from Operations for Q1 2026 stood at 165743000.0, down from 170069000.0 in the prior quarter.
- Over the last five years, Cash from Operations for ALKS reached as high as 215710000.0 in Q2 2023 and fell as low as 165743000.0 in Q1 2026.
- Historically, Cash from Operations has averaged 71560705.88 across 5 years, with a median of 98811000.0 in 2025.
- Across the five-year window, Cash from Operations jumped 15853.28% in 2023 and sank 267.74% in 2026, its largest moves.
- Year by year, Cash from Operations stood at 1047000.0 in 2022, then surged by 10142.31% to 107237000.0 in 2023, then soared by 77.55% to 190397000.0 in 2024, then retreated by 10.68% to 170069000.0 in 2025, then plunged by 197.46% to 165743000.0 in 2026.
- Per Business Quant data, the three most recent Cash from Operations figures were 165743000.0 in Q1 2026, 170069000.0 in Q4 2025, and 101672000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -40.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 401.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 463.30 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 388.30 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 145.80 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 13.00 Mn |
| 10 | Alkermes | 9.72 Bn | 9.21 Bn | 331.33 Mn | -165.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -165.74 Mn |
| Mar 31, 2026 | -165.74 Mn |
| Dec 31, 2025 | 170.07 Mn |
| Dec 31, 2025 | 170.07 Mn |
| Sep 30, 2025 | 101.67 Mn |
| Sep 30, 2025 | 101.67 Mn |
| Jun 30, 2025 | 150.20 Mn |
| Jun 30, 2025 | 150.20 Mn |
| Mar 31, 2025 | 98.81 Mn |
| Mar 31, 2025 | 98.81 Mn |
| Dec 31, 2024 | 190.40 Mn |
| Dec 31, 2024 | 190.40 Mn |
| Sep 30, 2024 | 81.59 Mn |
| Sep 30, 2024 | 81.59 Mn |
| Jun 30, 2024 | 146.03 Mn |
| Jun 30, 2024 | 146.03 Mn |
| Mar 31, 2024 | 21.11 Mn |
| Mar 31, 2024 | 21.11 Mn |
| Dec 31, 2023 | 107.24 Mn |
| Dec 31, 2023 | 107.24 Mn |